Stocks
Amgen Stock Surges as FDA Approval and Price Target Fuel Momentum
Amgen Inc., ticker AMGN, closed at $385.65 on September 18, 2026, after a 1.55 percent gain from the previous day's close. The pharmaceutical company has a market capitalization of $208.49 billion.
The stock is trading near its 52-week high of $447.03, according to MarketScreener, and BMO Capital Markets recently cut Amgen's rating to Market Perform from Outperform on September 8, 2026, with a price target of $450.
Amgen received FDA approval for reduced monitoring time for the first two doses of Imdelltra on September 14, 2026. This news adds a fresh catalyst to the stock's performance, but investors should balance this progress against analyst caution.